Evaluate multiple adverse events in crossover design bioequivalence clinical trials

被引:0
|
作者
Wang, Y
Li, LX
Wang, ZC
Wang, YH
机构
[1] Biogen Inc, Cambridge, MA 02142 USA
[2] Kunming Med Coll, Kunming 650031, Peoples R China
[3] Lenox Hill Hosp, New York, NY 10021 USA
来源
ACTA PHARMACOLOGICA SINICA | 2001年 / 22卷 / 02期
关键词
crossover clinical trial; adverse effects; repeated-measures analysis; statistical models;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
AIM: To establish a statistical model to appropriately evaluate the relationship between clinical adverse event and treatment. METHODS: By splitting the duration of each treatment period into several time intervals (use day as unit), a clinical adverse event was sampled in each time interval as presented or not presented. The number of presented cases was added for each time interval, and time of subjects spent in each time interval was cumulated as person-days. The onset of a clinical adverse event and its duration were represented as repeatedly measured count data. By using the generalized linear mixed model with fixed- and random-effects, the relative rate of clinical adverse events relative to different treatments was modeled by the generalized estimate equation (GEE) technique. RESULTS: Example shows that not only the onset of adverse events, but also its duration and total person-days subjects spent in study would influence the relative rate of clinic adverse events. CONCLUSION: Our proposed approach is a good alternative and supplemental method for evaluating clinical adverse events.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 50 条
  • [31] Inappropriate Grading of Adverse Events in Cancer Clinical Trials Reply
    Cristina, Valerie
    Mauer, Murielle
    Wagner, Anna Dorothea
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 269 - 270
  • [32] Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials
    Veitch, Zachary W.
    Shepshelovich, Daniel
    Gallagher, Christina
    Wang, Lisa
    Razak, Albiruni R. Abdul
    Spreafico, Anna
    Bedard, Philippe L.
    Siu, Lillian L.
    Minasian, Lori
    Hansen, Aaron R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08) : 980 - 988
  • [33] Adverse events of fluoxetine: Postmarketing compared with premarketing clinical trials
    Musa, MN
    Staneluis, JM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) : 874 - 874
  • [34] Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials
    Fonck, Simon
    Deserno, Thomas
    [J]. MEDINFO 2017: PRECISION HEALTHCARE THROUGH INFORMATICS, 2017, 245 : 1262 - 1262
  • [35] Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials
    Barmaz, Yves
    Menard, Timothe
    [J]. DRUG SAFETY, 2021, 44 (09) : 949 - 955
  • [36] Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials
    Yves Barmaz
    Timothé Ménard
    [J]. Drug Safety, 2021, 44 : 949 - 955
  • [37] The Rate of Adverse Events Related to Hypnosis During Clinical Trials
    Bollinger, Jared W.
    [J]. AMERICAN JOURNAL OF CLINICAL HYPNOSIS, 2018, 60 (04) : 357 - 366
  • [39] A call for improved reporting on serious adverse events in clinical trials
    Schutte, Aletta E.
    [J]. JOURNAL OF HYPERTENSION, 2019, 37 (11) : 2154 - 2155
  • [40] A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz? in Chinese healthy subjects
    Xu, Zhongnan
    Wang, Yanli
    Liu, Zhengzhi
    Zhang, Renjie
    Zhou, Yannan
    Yu, Jing
    Lan, Jing
    Liang, Wenzhong
    Liu, Guangwen
    Qu, Xinyao
    Chen, Jiahui
    Su, Zhengjie
    Yu, Shuang
    Cheng, Yang
    Wang, Wanhua
    Ren, Qing
    Deng, Qiaohuan
    Zhao, Yicheng
    Yang, Haimiao
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 109